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Abstract
Background: Metagenomic sequencing of respiratory microbial communities for pathogen identification in
pneumonia may help overcome the limitations of culture-based methods. We examined the feasibility and clinical
validity of rapid-turnaround metagenomics with Nanopore™ sequencing of clinical respiratory specimens.
Methods: We conducted a case-control study of mechanically-ventilated patients with pneumonia (nine culture-
positive and five culture-negative) and without pneumonia (eight controls). We collected endotracheal aspirates
and applied a microbial DNA enrichment method prior to metagenomic sequencing with the Oxford Nanopore
MinION device. For reference, we compared Nanopore results against clinical microbiologic cultures and bacterial
16S rRNA gene sequencing.
Results: Human DNA depletion enabled in depth sequencing of microbial communities. In culture-positive cases,
Nanopore revealed communities with high abundance of the bacterial or fungal species isolated by cultures. In four
cases with resistant clinical isolates, Nanopore detected antibiotic resistance genes corresponding to the
phenotypic resistance in antibiograms. In culture-negative pneumonia, Nanopore revealed probable bacterial
pathogens in 1/5 cases and Candida colonization in 3/5 cases. In controls, Nanopore showed high abundance of
oral bacteria in 5/8 subjects, and identified colonizing respiratory pathogens in other subjects. Nanopore and 16S
sequencing showed excellent concordance for the most abundant bacterial taxa.
Conclusions: We demonstrated technical feasibility and proof-of-concept clinical validity of Nanopore
metagenomics for severe pneumonia diagnosis, with striking concordance with positive microbiologic cultures, and
clinically actionable information obtained from sequencing in culture-negative samples. Prospective studies with
real-time metagenomics are warranted to examine the impact on antimicrobial decision-making and clinical
outcomes.
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Background
Pneumonia is a primary cause of morbidity and mortality
among adults, leading to more than one million hospitali-
zations every year and high rates of intensive care unit
(ICU) admission in the US [1]. The mainstay of pneumo-
nia management is early and appropriate antimicrobial
therapy targeting the causative pathogens, balanced with
preventing antibiotic overuse and emergence of resistance
[2]. Thus, timely and accurate identification of causal
pathogens is imperative yet remains challenging due to re-
liance on culture-based methods with low sensitivity and
long turnaround times (48~72 h to actionable results [3]).
Recently developed rapid polymerase-chain reaction
(PCR) tests represent a significant advancement in the
field [4], but these tests can only detect the presence/ab-
sence of selected panels of pathogens, and thus are not
comprehensive enough in breadth or resolution. Culture-
independent methods using next-generation sequencing
of microbial communities may help overcome the limita-
tions of current diagnostic testing [5–7].
Our group and others have provided proof-of-concept
evidence that sequencing of the bacterial 16S rRNA gene
(16S sequencing) in clinical respiratory specimens can
provide diagnostic insights beyond standard microbio-
logic cultures [5, 8–10]. Nevertheless, standard 16S
sequencing is not clinically applicable due to limited
resolution (providing only genus-level bacterial identifi-
cation) and lengthy sample processing, library prepar-
ation and data acquisition timelines [11]. The advent of
Nanopore metagenomic sequencing (Oxford Nanopore
Technologies [ONT], UK) has offered unprecedented
capacities for real-time, detailed profiling of microbial
communities at species level (including viruses and
fungi) [12–15]. With recent technical improvements to
overcome the high amounts of contaminating human
DNA in clinical respiratory samples [16], Nanopore
metagenomics may allow for the development of a novel
diagnostic approach for pneumonia.
In this proof-of-concept study, we sought to evaluate
the technical feasibility and clinical validity of Nanopore
metagenomic sequencing for etiologic diagnosis of se-
vere pneumonia in mechanically-ventilated patients in
the ICU. Some of the results of these studies have been
previously reported in the form of abstracts [17, 18].
Methods
Detailed methods are provided in the Additional file 1.
Study design and participants
From June 2018 – March 2019, we carried out a nested
case-control feasibility study from an ongoing registry
enrolling mechanically-ventilated adult patients with
acute respiratory failure in the Medical Intensive Care
Unit (MICU) at the University of Pittsburgh Medical
Center (UPMC) [5, 19]. Exclusion criteria included in-
ability to obtain informed consent, presence of tracheos-
tomy, or mechanical ventilation for more than 72 h prior
to enrollment.
Given the proof-of-concept nature of our study, we
aimed to identify cases and controls that would allow for a
meaningful comparison contrast of sequencing outputs.
Thus, we reviewed enrolled subjects during this recruit-
ment period to identify pneumonia cases with diagnostic
certainty on etiologic pathogen diagnosis (based on
clinically-available culture methods), probable pneumonia
cases with diagnostic uncertainty on the causative patho-
gen (culture-negative cases) and then, uninfected controls
with low or no suspicion of infection. Selection of cases
was done prior (and thus without knowledge) of DNA
sequencing or host-response biomarker experiments. We
diagnosed clinical pneumonia based on consensus commit-
tee review of clinical, radiographic, and microbiologic data
per established criteria [20]. Through the selection process
described above, we identified 14 subjects with a clinical
diagnosis of pneumonia: nine with culture-confirmed diag-
nosis (culture-positive pneumonia group) and five with
negative cultures (culture-negative pneumonia group).
Culture-positivity was deemed when a probable respiratory
pathogen was isolated in clinical microbiologic cultures of
respiratory specimens obtained at the discretion of treating
physicians (endotracheal aspirate [ETA] in 7 cases, and
bronchoalveolar lavage fluid [BALF] in 2 cases [case 2, case
3]). In culture-positive cases, antibiotic susceptibility testing
was done as per standard practice at UPMC’s clinical
microbiology laboratory, and results were interpreted based
on Clinical and Laboratory Standards Institute criteria [21].
We also included eight subjects (controls) who did not
have evidence of lower respiratory tract infection and were
intubated either for airway protection (n = 5) or respiratory
failure from cardiogenic pulmonary edema (n = 3).
From enrolled subjects, we collected ETAs per our re-
search protocol within the first 48 h from intubation
(baseline samples) and then on day 5 post-intubation if
the patient remained on mechanical ventilation in the
ICU [19, 22]. For the purposes of comparing ETA sequen-
cing results with clinical microbiologic cultures, we uti-
lized baseline samples in 20/22 subjects, because baseline
samples were closer to the timing of clinical microbiologic
specimen acquisition for diagnosis of index pneumonia
(not ventilator-associated pneumonia [VAP]). In two sub-
jects, we utilized ETAs obtained on the fifth day post-
intubation (instead of their baseline samples) because in
one case (case 10, Additional file 1: Figure S1) the day 5
sample was obtained closer to the timing of clinical cul-
tures for clinical suspicion of VAP, whereas in case 15 the
day 5 sample was obtained at a time point that earlier clin-
ical suspicion of pneumonia was refuted and antibiotics
were stopped (congestive heart failure control). We
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utilized only a single specimen per patient in order to
maintain our diagnostic inference analyses on patient-
level (and not sample-level). From plasma samples taken
at the same time with ETAs, we measured plasma procal-
citonin levels [19]. We recorded demographic, physio-
logical, and laboratory variables at the time of sample
acquisition, from which we calculated clinical pulmonary
infection scores (CPIS) [23], and reviewed the antimicro-
bial therapies administered for the first 10 days from
intubation.
This study was approved by the University of Pittsburgh
Institutional Review Board (Protocol PRO10110387).
Written informed consent was provided by all participants
or their surrogates in accordance with the Declaration of
Helsinki.
Microbial DNA sequencing approaches
We focused our sequencing approach on DNA-based or-
ganisms (i.e. excluding RNA viruses) and aimed to perform
agnostic profiling for microbes (bacteria and fungi) present
in the ETAs obtained from the patients in the ICU. We
performed direct-from-sample sequencing and we did not
use isolated organisms from clinical cultures for sequen-
cing. However, metagenomic microbial DNA sequencing
in clinical respiratory samples is technically challenging be-
cause of the high amounts of contaminating human DNA
that can overwhelm the sequencing output (ratio of hu-
man:microbial DNA > 99:1 [24]. Therefore, we applied a
human DNA depletion step in ETA samples that utilized a
detergent-based (saponin) method for selective lysis of hu-
man cells and digestion of human DNA with nuclease, as
recently described [16]. We extracted genomic DNA with
the DNeasy Powersoil Kit (Qiagen, Germantown, MD) and
assessed the efficiency of human DNA depletion by com-
paring quantitative PCR (qPCR) cycle threshold (Ct) of a
human gene (Glyceraldehyde 3-phosphate dehydrogenase -
GAPDH) and the bacterial 16S rRNA gene (V3-V4 region)
[25] between samples subjected to depletion vs. not (de-
pleted vs. undepleted samples).
From extracted DNA in depleted samples, we prepared
metagenomic sequencing libraries with a Rapid PCR Bar-
coding Kit (SQK-RPB004) and then ran on the MinION
device [Oxford Nanopore Technologies (ONT), UK)] for
5 h. We basecalled the output (i.e. converted the sequen-
cing device output into nucleic acid base sequences) with
the Guppy software and used the ONT platform, EPI2ME,
for quality control, species identification [What’s In My
Pot (WIMP) pipeline] and antimicrobial resistance gene
analyses [ARMA workflow]. Samples that generated fewer
than 300 high-quality microbial reads were excluded from
further analyses. As an internal quality control for the reli-
ability and reproducibility of Nanopore sequencing, we
performed sequencing on two samples with extracted
DNA from a mock microbial community with known
composition (ZymoBIOMICS Microbial Community
Standard) and compared derived vs. expected abundance
of microbial species.
To further validate the results of Nanopore sequencing
for bacterial DNA, we performed standard 16S rRNA
gene (V4 region) PCR amplification and sequencing on
the Illumina MiSeq Platform as a reference method for
bacterial DNA sequencing [26]. We processed 16S se-
quences using an in-house pipeline developed by the
University of Pittsburgh Center for Medicine and the
Microbiome (CMM) [22, 27–31]. Samples that generated
fewer than 100 bacterial reads were excluded from fur-
ther analyses.
Ecological and statistical analyses
From sequencing reads obtained from Nanopore and 16S
sequencing, we calculated alpha diversity by Shannon
index, performed permutational multivariate analysis of
variance (PERMANOVA) testing to assess compositional
differences between sample types, and visualized compos-
itional dissimilarities between samples with the non-
metric multidimensional scaling (NMDS) method using
the Bray-Curtis index. All analyses were performed with
the R vegan package [32].
Results
Cohort description
We enrolled 22 mechanical-ventilated patients with
acute respiratory failure: nine with retrospective con-
sensus diagnosis of culture-positive pneumonia, five
with culture-negative pneumonia, and eight controls.
Clinical characteristics and outcomes for the three
groups are shown in Table 1. Cases with culture-
positive pneumonia had significantly higher CPIS and
a trend for higher procalcitonin levels compared to
controls (Table 1, Additional file 1: Figure S2). At the
time of enrollment, empiric antibiotics had been pre-
scribed for all 14 patients with clinical diagnosis of
pneumonia, as well as for 5/8 of control patients
(Table 1, Additional file 1: Figure S1).
Technical feasibility of Nanopore sequencing in clinical
samples
Pre-processing of the ETA samples with the saponin-
based human DNA depletion protocol resulted in rela-
tive enrichment of bacterial DNA by an average of
1260-fold (Additional file 1: Figure S3). This microbial
enrichment step allowed for generation of sufficient
numbers of microbial reads by Nanopore sequencing
in depleted samples (median 6682 reads, average pro-
portion 48% of total reads), whereas in undepleted samples
the sequencing output was overwhelmed by human DNA
(only 1% of reads were of microbial origin) and effectively
was unusable (Fig. 1a). Although this enrichment step
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allowed for generation of analyzable sequencing output in
depleted samples (i.e. 48% of total reads), we sought to define
whether the depletion protocol altered the underlying micro-
bial communities in any detectable way. For that reason, we
compared 16S rRNA gene sequencing profiles between de-
pleted and undepleted samples. We elected to perform 16S-
based comparisons because amplicon-based sequencing
methods are unaffected by the amount of contaminating hu-
man DNA. Importantly, depleted and undepleted samples by
16S rRNA gene sequencing demonstrated no significant dif-
ferences in alpha or beta diversity (Fig. 1b, c), suggesting that
the underlying microbial community in depleted samples
was closely representative of the raw, undepleted samples
that were not subjected to any additional processing.
Analytical validity of Nanopore sequencing
Nanopore-derived bacterial communities showed strik-
ing similarity with both mock communities of extracted
DNA (Additional file 1: Table S1) as well as 16S-derived
community profiles for bacteria from clinical samples
(Additional file 1: Figure S1), underscoring the analytical
validity of Nanopore results for use in further analyses.
Nanopore community profiles by clinical group
By Nanopore sequencing, culture-positive samples had a
trend for lower alpha diversity (Shannon index) compared
to culture-negative samples (Fig. 2a and Additional file 1:
Figure S4A) and demonstrated global compositional
dissimilarities compared to culture-negative and control
Table 1 Characteristics of enrolled patients. Continuous variables are presented as medians (with interquartile ranges), and
categorical variables are presented as N (%)
Culture-Positive
Pneumonia
Culture-Negative
Pneumonia
Controls
N 9 5 8
Age, median [IQR], yrs 58.3 [55.2, 62.6] 55.8 [45.7, 62.8] 61.2 [51.9, 67.4]
Male, N (%) 5 (55.6) 2 (40.0) 6 (75.0)
BMI, median [IQR] 24.0 [21.5, 34.6] 31.2 [25.6, 32.9] 28.1 [25.1, 36.1]
SOFA Score, median [IQR]a 6.0 [4.0, 6.0] 7.0 [6.0, 7.0] 5.0 [4.0, 8.0]
PaO2:FIO2 ratio, median [IQR], mmHg 158.0 [137.0, 275.0] 150.0 [121.0, 208.0] 221.5 [205.0, 319.5]
Heart rate (median [IQR]), beats per minute 107.0 [92.0, 117.0] 83.0 [82.0, 88.0] 81.5 [73.8, 85.5]
SBP (median [IQR]) mmHg 125.0 [102.0, 141.0] 118.0 [117.0, 127.0] 105.0 [97.8, 117.5]
WBC, median [IQR], × 109 per liter (L) 10.0 [7.4, 16.8] 4.6 [3.5, 8.3] 5.4 [4.5, 11.6]
Platelets, median [IQR], × 109 per liter (L) 190.0 [169.0, 281.0] 155.0 [136.0, 210.0] 141.0 [72.2, 171.0]
Creatinine, median [IQR], mg/dL 1.3 [1.1, 1.5] 1.5 [1.5, 2.0] 1.0 [0.8, 1.4]
Respiratory Rate, median [IQR], 1/min 22.0 [21.0, 24.0] 21.0 [20.0, 24.0] 17.0 [15.5, 17.2]
PEEP, median [IQR], cm 8.0 [5.0, 8.0] 5.0 [5.0, 8.0] 5.0 [5.0, 5.8]
Tidal Volume (per kg of PBW), (median [IQR]), ml/kg 6.8 [6.2, 8.4] 6.2 [6.1, 6.6] 6.3 [6.0, 7.1]
Plateau Pressure, median [IQR], cm 20.0 [13.0, 23.5] 25.0 [21.0, 29.0] 16.0 [13.0, 21.5]
Type of mechanical breaths, n (%)b
Volume control 7 (77.8) 4 (80.0) 8 (100)
Pressure control 2 (22.2) 1 (20.0) 0 (0)
Ventilator free days, median [IQR], days 12.0 [0.0, 23.0] 17.0 [6.0, 23.0] 24.5 [24.0, 26.0]
ICU Length of Stay, median [IQR], days 8.0 [5.0, 18.0] 11.0 [6.0, 12.0] 4.5 [3.8, 5.0]
Acute Kidney Injury, N (%) 8 (88.9) 4 (80.0) 2 (25.0)
30 Day Mortality, N (%) 3 (33.3) 1 (20.0) 1 (12.5)
On antibiotic therapy, N (%) 9 (100) 5 (100) 5 (62.5)
Antibiotic days, median [IQR], days 12.0 [10.0, 24.0] 21.0 [20.0, 24.0] 3.5 [0.0, 7.5]
CPIS, median [IQR], 8.0 [7.0, 9.0] 6.0 [5.0, 7.0] 5.0 [4.0, 5.2]
Procalcitonin, median [IQR], pg/μl 2783.0 [1049.5, 4330.1] 4866.0 [94.4, 4965.1] 353.5 [250.4, 1531.6]
Abbreviations: IQR Interquartile range, BMI Body mass index, SOFA Sequential organ failure assessment, PaO2 Partial pressure of arterial oxygen, FiO2 Fractional
inhaled concentration of oxygen, SBP Systolic blood pressure, WBC White blood cell count, PEEP Positive end-expiratory pressure, PBW Predicted body weight, ICU
Intensive care unit, CPIS Clinical pulmonary infection score
a SOFA score calculation does not include the neurologic component of SOFA score because all patients were intubated and receiving sedative medications,
impairing our ability to perform assessment of the Glasgow Coma Scale in a consistent and reproducible fashion
b All patients were on assist controls mode of ventilation at time of sample acquisition
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Fig. 1 Saponin-based human DNA depletion effectively removed human DNA without changing bacterial community structure. a Before human
DNA depletion, 1% of Nanopore reads were of microbial origin; following human DNA depletion, 48% of Nanopore reads were of Microbial
origin. b There was no significant difference in alpha diversity of bacterial communities between depleted and undepleted samples assessed by
16S rRNA gene sequencing. c Non-metric multidimensional scaling (NMDS) plot of the Bray-Curtis dissimilarity index between depleted and
undepleted samples based on 16S rRNA gene sequencing. Depleted samples were compositionally similar to undepleted samples
(PERMANOVA, p-value = 0.17)
Fig. 2 Comparisons of lung microbiome between culture-positive pneumonia, culture-negative pneumonia and controls based on Nanopore
sequencing. a Compared to samples from patients with culture-negative pneumonia, culture-positive samples had a trend for lower alpha
diversity of lung microbial communities by Shannon index. b By non-metric multidimensional scaling (NMDS) plot of the Bray-Curtis dissimilarity
index, there were significant differences in overall microbial community compositions between three groups (PERMANOVA for Bray-Curtis
dissimilarity index, p value= 0.038, R2 = 0.120)
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samples (PERMANOVA p-value = 0.038, R2 = 0.12, Fig. 2b
and Additional file 1: Figure S4B).
Nanopore-based pathogen identification
Culture-positive pneumonia
We first examined Nanopore results in the culture-
positive cases in which microbiologic confirmation of
the causative pathogen allowed for a targeted interroga-
tion of the sequencing output for the corresponding mi-
crobial species. We examined different thresholds of
sequencing output (i.e. absolute number of reads for the
dominant pathogen vs. relative or ranked abundance
thresholds for pathogens) to maximize sensitivity of
Nanopore results for detecting the culture-identified
pathogen(s). By focusing on the three most abundant
species (bacterial or fungal) by Nanopore sequencing, we
were able to identify all culture-confirmed pathogens
with high relative abundances.
In eight culture-positive bacterial pneumonias, Nano-
pore profiles showed high abundance of the same bac-
terial species isolated in cultures (Fig. 3a). These highly
abundant causative bacterial pathogens had on average
90 times higher relative abundance compared to the spe-
cies ranked second in abundance in each community
(Fig. 3b). Nanopore sequencing also revealed high abun-
dance of additional potential bacterial pathogens in 2/8
of samples that were not detected by cultures (E. coli in
subject 1 and H. influenzae in subject 8), suggesting the
presence of a polymicrobial infection despite the isola-
tion of a single pathogenic bacterial species on standard
cultures (Fig. 3a).
These eight culture-positive cases with clinical antibio-
grams allowed for examination of the potential predict-
ive utility of antibiotic resistance gene detection with
metagenomic sequencing (Table 2). In the single case of
methicillin-resistant Staphylococcus aureus (MRSA, case
2, Additional file 1: Figure S1), Nanopore detected 4
reads aligned to the responsible mecA gene, whereas in
the three cases of methicillin-sensitive S. aureus (MSSA,
cases 3, 5 and 6), no mecA gene reads were detected.
Similarly, in the two cases of Stenotrophomonas malto-
philia and E.coli, Nanopore detected genes that ex-
plained the observed phenotypic antimicrobial resistance
profile (Table 2).
We also tested the performance of Nanopore sequen-
cing in one case with probable invasive fungal infection.
Subject 9 was a lung transplant recipient who had been
receiving antifungal therapy for a positive sputum cul-
ture for Aspergillus fumigatus. Clinical decompensation
with acute respiratory failure raised concern for bacterial
co-infection and initiation of intensive broad-spectrum
antibiotics. BALF culture grew again Aspergillus fumiga-
tus, which was the dominant pathogen detected by
Nanopore, without any other sequencing evidence of
bacterial infection (Fig. 3c). Thus, in this case with prob-
able invasive fungal infection, Nanopore sequencing only
identified a confirmed fungal pathogen and ruled out the
presence of bacterial pneumonia.
Culture-negative pneumonia
Nanopore sequencing provided diverse representations
of microbial communities in cases of clinical suspi-
cion of pneumonia with negative cultures, and thus
interpretation needs to be individualized for each case
(Additional file 1: Figure S1).
In case 10 with an initial diagnosis of aspiration pneu-
monia caused by S. aureus and Klebsiella oxytoca identi-
fied by BALF culture on day 2 post-intubation, clinical
deterioration on appropriate antibiotic therapy and new
radiographic infiltrates by day 5 raised concern for VAP.
However, repeat BALF culture on day 5 was negative.
Nanopore detected high abundance of both S. aureus
and Klebsiella oxytoca on day 5 sample, revealing that
the culture-negative community consisted of abundant
previously identified pathogens, which were likely not vi-
able at the time of the day 5 BALF acquisition due to
ongoing antibiotic therapy. Moreover, low procalcitonin
level at the time of the day 5 sample (94 pg/μl) and ab-
sence of new pathogens by sequencing made diagnosis
of new VAP unlikely.
In another case of a lung transplant recipient (subject
11) with diffuse bilateral consolidations and persistent
clinical septic picture of undefined etiology, BALF culture
was only positive for yeast and the patient was empirically
treated with broad-spectrum antibiotics. Eventually, the
patient was proven to be fungemic with delayed growth of
Candida glabrata on initial blood cultures prompting
addition of antifungal therapy. Nanopore sequencing on
ETA sample from day 1 post-intubation showed high
abundance of Candida glabrata and Candida dubliniensis
with very low abundance of bacterial reads, confirming
the absence of bacterial pneumonia and demonstrating
fungal colonization of the allograft. Of note, in two other
culture-negative cases, Nanopore also detected high abun-
dance of Candida albicans (Fig. 3d), whereas in the last
case, both Nanopore and 16S sequencing identified abun-
dant oral bacteria with no typical respiratory pathogens.
Controls
Eight control subjects did not meet clinical diagnostic
criteria for pneumonia on retrospective examination of
their clinical course. Despite not meeting diagnostic
criteria, 5/8 cases empiric antibiotics were prescribed
empiric antibiotics early in their course for initial con-
sideration of possible pneumonia. Five samples were
dominated by common oral bacteria, such as Rothia and
non-pneumoniae Streptococcus species [33, 34]. How-
ever, in the other three samples, Nanopore and 16S
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Fig. 3 (See legend on next page.)
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sequencing detected potential respiratory pathogens (e.g.
S.aureus, H. influenzae or S. pneumoniae) that were
likely airway colonizers not causing clinical infection,
notion supported by clinical improvement despite early
discontinuation of antibiotics and/or low procalcitonin
levels (Additional file 1: Figure S1). No significant fungal
DNA presence was detected by Nanopore sequencing in
the control group (Fig. 3e).
Discussion
In this nested case-control study, we provide proof-of-
concept evidence that untargeted, shotgun metagenomic
sequencing with the MinION device can reveal clinically
useful information for etiologic diagnosis of pneumonia
in mechanically-ventilated patients. We demonstrate
feasibility of metagenomic sequencing directly from clin-
ical respiratory specimens by applying a saponin-based
protocol for human DNA depletion prior to sequencing.
Our analyses highlighted global microbial community
structure and species-level compositional differences as-
sociated with culture-positivity and clinical diagnosis of
pneumonia. Nanopore sequencing had good concord-
ance with cultures by detecting high abundance of the
causative pathogenic bacteria in culture-positive cases,
but also revealed profiles with low abundance of typical
respiratory pathogens in selected culture-negative cases
with clinical suspicion of bacterial pneumonia.
Nanopore metagenomic sequencing holds promise as
a potential diagnostic tool due to its comprehensive
scope, in-depth resolution with long read sequencing
and real-time data generation [6]. However, contaminat-
ing human DNA has been a rate-limiting step for clinical
implementation. By applying a recently validated proto-
col with saponin-based, human DNA depletion [16], we
demonstrate that this approach is feasible, reproducible
and effective for maximizing the microbial signal in clin-
ical samples and providing interpretable sequencing
output.
Nanopore sequencing showed high accuracy in patho-
gen identification in culture-positive pneumonia. The high
concordance of our sequencing results with clinically-
obtained microbiologic studies, despite the use of different
samples (research ETAs vs. clinical ETA or BALF)
highlights the robustness of DNA-based sequencing ap-
proaches for pathogen identification. Obviating the need
for ex-vivo growth for organisms, direct-from-sample se-
quencing can offer comprehensive snapshots of the com-
ponent microbes of the communities at the time of
sample acquisition. Sequencing methods are thus robust
to specific growth condition requirements or the impaired
viability of organisms due to antecedent antimicrobials
[35]. In exploratory analyses of the sequencing output,
Nanopore also provided antibiotic resistance information
by detecting clinically relevant resistance genes that
matched the phenotypic resistance on antibiograms (e.g.
mecA detection/absence in MRSA/MSSA cases, respect-
ively). Overall, rapid metagenomic sequencing closely
matched the results of current, reference-standard diag-
nostic methods in our cohort, which typically take 2–3
days for allowing appropriate antibiotic adjustments to
occur. Thus, with further external validation in additional
cohorts, nanopore metagenomics have the potential to
shorten the time to etiologic diagnosis and appropriate
antimicrobial therapy selection.
Invasive pulmonary fungal infections represent a major
diagnostic challenge due to the poor sensitivity and slow
turnaround times of cultures [36]. In the single case of
Aspergillus fumigatus infection, Nanopore confirmed the
high abundance of Aspergillus fumigatus in the commu-
nity and ruled out concomitant bacterial pneumonia.
Such results can directly influence clinical practice, as
unnecessary and potentially harmful antibiotics could be
discontinued, with antimicrobial therapies focused on
the causative fungal pathogen [37].
In cases of culture-negative pneumonia and in con-
trols, the main compositional pattern consisted of di-
verse communities with oral bacteria abundance [5],
similar to clinical microbiology reports of normal re-
spiratory flora. In such cases, early de-escalation or dis-
continuation of antibiotics could be further supported
by sequencing results. Nonetheless, in 3/5 airway con-
trols, potential respiratory pathogens were detected in
high abundance by both Nanopore and 16S sequencing,
in the absence of other supportive evidence of pneumo-
nia. Such cases highlight an important clinical challenge
that can emerge from the high sensitivity of sequencing
(See figure on previous page.)
Fig. 3 Comparisons of microbes detected by Nanopore metagenomic sequencing and clinical culture. Each small plot represents an
endotracheal aspirate; each bar represents a microbe; the X-axis represents the relative abundance of microbes by Nanopore. Petri dish
represents pathogen isolated by clinical culture. The three most abundant taxa detected by Nanopore sequencing were included. a In 8 samples
with culture-positive bacterial pneumonia, Nanopore signals were dominated by pathogens isolated by culture. b In 8 samples with culture-
positive bacterial pneumonia, the relative abundance of culture-positive pathogens was 90-times higher than that of the second-ranked taxa
detected by Nanopore. c In 1 sample with probable invasive fungal infection, chest radiograph supported a clinical diagnosis of pneumonia,
Aspergillus fumigatus was isolated by culture, and Nanopore revealed the same fungal pathogen by sequencing. d In 5 culture-negative
pneumonia samples, potential pathogens were found in one sample, and fungi were found in 3 samples with Nanopore. e Only typical oral
bacteria were identified in 5/8 of control samples, but potential pathogens were detected in 3/8 of them. * compared to culture of pleural fluid;
** case of culture-positive tracheobronchitis and acute exacerbation of chronic obstructive pulmonary disease (no infiltrate on chest radiograph)
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technologies for identifying pathogenic organisms
missed by cultures. Detection of abundant DNA from
respiratory pathogens in the airways of mechanically-
ventilated patients does not translate into a clinical
diagnosis of pneumonia or need for antibiotic adminis-
tration. As the field of sequencing-based diagnostics is
nascent, we currently do not have diagnostic thresholds
for distinguishing colonizing vs. infecting organisms,
Table 2 Comparison of antibiotic resistance phenotype and clinically relevant resistance genes in cases of bacterial pneumonia. The
antibiotic resistance phenotype was detected by clinical culture and clinically relevant resistance genes were detected by Nanopore.
Genes conferring resistance phenotype are highlighted in bold
Case Pathogen by culture & Nanopore Resistance phenotype by culture Clinically relevant resistance genes
[N of alignments]
Resistance identified
Case 1 Stenotrophomonas maltophilia R: ticarcillin/clavulanic acid
R: ceftazidime
blaTEM-4 [4]
blaTEM-112 [1]
blaTEM-157 [1]
blaACT-5 [1]
I: levofloxacin oqxB [1]
Tetracycline not tested tetC [6]
Case 2 Staphylococcus aureus R: methicillin mecA [4]
R: erythromycin, clindamycin ermA [10]
erm (33) [1]
tet38 [11]
ant(4′)-lb [9]
tetC [3]
blaTEM-4 [1]
Case 3 Staphylococcus aureus I: tetracycline tetK [1]
tet38 [1]
tetQ [1]
Case 4 Escherichia coli R: tetracycline tetX [1]
R: Trimethoprim-sulfamethoxazole
R: ciprofloxacin, levofloxacin
sul1 [363]
dfrA [127]
acrF [315]a
parE [304]a
mfd [277]a
mphA [215]
aadA5 [196]
vgaC [110]
blaACT-5 [7]
blaACT-14 [3]
mefA [1]
mel [1]
No resistance identified
Case 5 Staphylococcus aureus S: all tested agents none
Case 6 Staphylococcus aureus S: all tested agents tet38 [2]
blaTEM4 [2]
Case 7 Pseudomonas aeruginosa S: all tested agents none
Resistance not tested
Case 8 Streptococcus agalactiae Not tested tetM [60]
isaC [55]
sul1 [2]
tetQ [2]
mphA [1]
aadA5 [1]
Abbreviations: R Resistant, I Intermediate, S Susceptible
a Genes conferring antibiotic resistance phenotype but not classified as clinical relevant genes by EPI2ME antimicrobial resistance gene analyses [ARMA workflow]
Tested agents for case 5: Ampicillin/Sulbactum, Oxacillin, Imipenem, Gentamicin, Erthromycin, Tetracycline, Vancomycin, Clindamycin, Linezolid, Rifampin,
Trimethoprim-sulfamethoxazole, Synercid
Tested agents for case 6: Ampicillin/Sulbactum, Oxacillin, Imipenem, Gentamicin, Erthromycin, Tetracycline
Tested agents for case 7: Piperacillin/Tazobactum, Ticarcillin/Clavulanic acid, Cefepime, Ceftazidime, Imipenem, Meropenem, Aztreonam, Gentamicin, Tobramycin,
Amikacin, Ciprofloxacin, Levofloxacin
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similar to the ones considered for culture-based methods
based on numbers of colony-forming units [38]. How-
ever, the distinction between colonization and infection
cannot be based solely on culture results or microbial
DNA sequencing outputs, but needs to be an integrative
one, incorporating clinical, radiographic, and systemic/
focal host-responses [39–41]. With the introduction of
RNA-based sequencing, a simultaneous assessment of
microbial community profiles with the corresponding
host transcriptomics at the local level may offer further
diagnostic insights [40]. At the same time, knowledge of
colonizing organisms in critically-ill patients can facili-
tate more targeted choices for initial antibiotic regimens
in the event of a secondary infection, such as VAP.
Our study is limited by the single center design and the
available sample size. We did not perform Nanopore se-
quencing and data analyses in real-time because of our
retrospective study design, and our objective of demonstrat-
ing proof-of-concept feasibility as opposed to practical clin-
ical utility. Nonetheless, the method is implementable with
short turnaround times (~ 6-8 h) [13]. The results of anti-
biotic resistance gene sequencing should be interpreted
with caution, and development of reliable predictive rules
for pneumonia diagnosis or resistance gene identification
based on sequencing outputs will require prospective exam-
ination of large cohorts of patient samples. Finally, the
human DNA depletion method we applied is not yet opti-
mized for viral DNA detection [16].
In conclusion, our study demonstrates technical feasibil-
ity and clinical validity of direct-from-specimen metage-
nomics with a rapid protocol for human DNA depletion
protocol and sequencing with the MiNION device. Meta-
genomic approaches hold promise for the development of
rapid and comprehensive diagnostic tools for severe pneu-
monia that could transform the existing diagnostic para-
digm. With real-time data generation and turnaround
times of 6-8 h from sample acquisition to result, rapid
metagenomics could conceivably allow for targeted adjust-
ment of initial empiric antibiotic regimens even before
their second dose is due, and thus allow for personalized
antimicrobial prescriptions and antibiotic stewardship
gains. Our results provide rationale for prospective, large-
scale studies with real-time application of metagenomics
in order to measure the direct impact on antibiotic guid-
ance and clinical outcomes.
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